News

The program intends to develop an advanced system for early cancer detection by employing acoustic liquid handling for arraying and MALDI mass spectrometry preparation. Stanford University Canary Center

As per the agreement, ORCA will receive €1,058,000 to carry out the first phase of the project, with an expected additional funding of about €5m on achieving specific

Under the terms of the deal, Perrigo will supply its Bright Beginnings infant formula brand to Brilite. Brilite, on the other hand, will exclusively source all its infant

The fast track status will facilitate to develop and expedite the review of drugs intended to treat serious or life-threatening conditions. The fast track priority review products are

The transaction is expected to close by the end of 2011, subject to routine closing conditions, including Hart-Scott-Rodino antitrust approval. Oceana Business Development executive vice president Gregory Stokes

Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement. ECLIPSE II is an open-label, dose-escalating study, where CYT107 was administered subcutaneously, one injection

TC-5214, a nicotinic channel modulator serves as an adjunct treatment for MDD in patients with an inadequate response to initial antidepressant therapies. The Renaissance clinical trial programme consists

The integration of the LifeOnKey EHR with Target eCRF helps the clinical research investigator maintain the original source document or a certified copy. In addition, source data can

The pharmacodiagnostic tests are intended to identify the patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb. Dakos CEO Lars Holmkvist